Búsqueda | Portal Regional de la BVS

Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.

Nagao, Shoji; Fujiwara, Keiichi; Yamamoto, Kouji; Tanabe, Hiroshi; Okamoto, Aikou; Takehara, Kazuhiro; Saito, Motoaki; Fujiwara, Hiroyuki; Tan, David S P; Yamaguchi, Satoshi; Adachi, Sosuke; Kikuchi, Akira; Hirasawa, Takeshi; Yokoi, Takeshi; Nagai, Tomonori; Sato, Toyomi; Kamiura, Shoji; Fujishita, Akira; Loong, Wong Wai; Chan, Karen; Syks, Peter; Olawaye, Alexsander; Ryu, Sang-Young; Shigeta, Hiroyuki; Kondo, Eiji; Yokoyama, Yoshihito; Matsumoto, Takashi; Hasegawa, Kosei; Enomoto, Takayuki.

NEJM Evid ; 2(5): EVIDoa2200225, 2023 May.

Artículo en Inglés | MEDLINE | ID: mdl-38320049

RESUMEN

Intraperitoneal Carboplatin for Ovarian CancerThis trial compared intravenous weekly paclitaxel administered with intraperitoneal or intravenous carboplatin. There was a statistically significant increase in progression-free survival in patients with ovarian cancer treated with intraperitoneal versus intravenous carboplatin and paclitaxel, with no difference in overall survival between groups.

Asunto(s)

Neoplasias Ováricas , Humanos , Femenino , Carboplatino , Neoplasias Ováricas/tratamiento farmacológico , Paclitaxel , Supervivencia sin Progresión , Administración Intravenosa

Ver mas detalles

ENVIAR RESULTADO:

Exportar

Imprimir

RSS

XML

RESUMEN

Asunto(s)

ENVIAR RESULTADO:

SELECCIÓN DE REFERENCIAS

DETALLE DE LA BÚSQUEDA